<DOC>
	<DOCNO>NCT02244281</DOCNO>
	<brief_summary>1 . To study symptomatic improvement LUTS afford FLOMAX® capsule , 0.4 mg daily compare placebo , female patient low urinary tract symptom ( LUTS ) significant component void symptom 2 . To study improvement afford FLOMAX® capsule versus placebo , patient population , quality life 3 . To assess safety tolerability FLOMAX® capsule , 0.4 mg compare placebo , woman suffer LUTS significant component voiding symptom</brief_summary>
	<brief_title>Study FLOMAX® Versus Placebo Female Patients With Lower Urinary Tract Symptoms ( LUTS ) With Significant Component Voiding Symptoms</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Tamsulosin</mesh_term>
	<criteria>Adult woman , 18 year age old , currently diagnose LUTS significant component void symptom The Patient must diagnose one following : hesitancy , intermittency , difficulty bladder empty , strain void Patients must AUA Symptom Score 13 high Obstruction component AUA Symptom Score ( Items 1 , 3 , 5 , 6 ) 5 point high Patients currently take alphablockers anticholinergic must discontinue drug least 2 week prior Visit 1 Patients show compliance great equal 80 % placebo usage Patients surgically sterile , 2 year postmenopausal , practice medically acceptable method birth control Patients must negative urine Beta Human Chorionic Gonadotropin ( betaHCG ) Patients must able provide write informed consent prior participation study accordance regulatory requirement Patients must judge investigator reliable comply test examination stipulate protocol All patient able understand read English Patients present active urinary tract infection present two culture positive urinary tract infection within 6 month study Patients significant prolapse beyond hymenal ring , per investigator 's judgment Patients take anticholinergic medication treatment urologic condition discontinue use 2 week prior study entry Patients history active condition renal urethral calculus , urethral colic , mechanical outlet obstruction ( i.e. , bladder neck contracture stricture , bladder tumor , bladder calculus ) 3 month prior study entry Patients history bladder , vaginal urethral surgery last 6 month Patients history microscopic hematuria recent workup include cystoscopy upper urinary tract study ( within 6 month screen ) diagnosis condition may exclude patient opinion investigator Abnormal urinalysis define follow midstream , cleancatch specimen result : A bacterial colony count great 100,000/ml . More 10 leukocyte per high power field two granular cast per high power field . More 10 red blood cell ( nonmenstrual taint urine sample ) per high power field . Proteinuria &gt; +1 ( equivalent &gt; 30 mg/dL ) Patients present follow : history neurogenic bladder due neurologic condition might involve low urinary tract , active urinary stone disease , previous pelvic radiotherapy , perirectal inflammatory disorder inflammatory bowel disease Patients history sexually transmit disease genitourinary system syphilis , herpes , gonorrhea , chlamydia , mycoplasma , trichomonas ( within 3 month study ) diagnosis opinion investigator may exclude patient Patients pregnant breastfeed The Patient significant pelvic pain demand treatment narcotic Large fluctuation LUTS symptom last 6 month ( i.e. , symptom appear disappear unusual rapidity ) Any baseline ( Visit 1 ) laboratory serum test follow value : Hemoglobin : &lt; 11.0 g/dL , Leukocytes : &lt; 3,000 per mm3 , Liver enzymes [ serum glutamic oxaloacetic transaminase / Aspartate aminotransferase ( SGOT/AST ) , serum glutamic pyruvic transaminase / Alanine transaminase ( SGPT/ALT ) alkaline phosphatase ] : two time upper limit normal baseline ( Visit 1 ) . Serum creatinine two time upper limit normal baseline ( Visit 1 ) Patients diagnosis cancer , except basal cell carcinoma , within past 5 year . ( Note : Contact Trial Clinical Monitor specific special circumstance regard entry cancer patient . ) Participation another drug study within 4 week baseline ( Visit 1 ) Clinically relevant condition may interfere patient 's ability participate study include , limited , follow : neurologic , gastrointestinal , cardiovascular , hepatic , renal , psychiatric , hematologic respiratory disease clinically relevant laboratory abnormality mention ( e.g. , hematuria ) base upon clinical judgment investigator Patients receive cimetidine , ranitidine warfarin medication within 2 week screen would potentially use medication course trial Patients know hypersensitivity FLOMAX® ( tamsulosin hydrochloride ) alphablockers Patients history myocardial infarction within 6 month baseline ( Visit 1 ) Patients uncontrolled hypertension ( systolic &gt; 160 mmHg , diastolic &gt; 100 mmHg ) patient severe hypotension ( systolic &lt; 90 mmHg ) 5 minute sit Patients use follow drug , within 2 week prior screen ( Visit 1 ) , unable discontinue drug course study 1 . Alphaadrenergic block agent 2 . Alphaadrenergic medication 3 . Drugs systemic anticholinergic activity include antihistamine . Antihistamines allow Allegra® , Claritin® Zyrtec® 4 . Antispasmodics muscle relaxant 5 . Parasympathomimetics , cholinomimetics , and/or similar drug Patients poorly control diabetes mellitus base upon urine 2+ ( great ) glucose urinalysis , perform screening ( Visit 1 ) . Patients suffer neurological disease affect bladder ( i.e. , multiple sclerosis , Parkinson 's disease , stroke , bladder trauma may exclusion criterion opinion investigator ) Patients neurological impairment psychiatric disorder prevents comprehension consent ability comply protocol Patients diagnose interstitial cystitis accord National Institute Diabetes Digestive Kidney Diseases ( NIDDK ) criterion Patients history urethral syndrome whose treatment dilation . Patients treat dilation 3 month prior study entry allow participate study</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>